Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression

11 Feb 2020

Abstract excerpt

The best-known role of UDP-glucuronosyltransferase enzymes (UGTs) in cancer is the metabolic inactivation of drug therapies. By conjugating glucuronic acid to lipophilic drugs, UGTs impair the biological activity and enhance the water solubility of these agents, driving their elimination. Multiple clinical observations support an expanding role for UGTs as modulators of the drug response and in mediating drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Drug Transport and Resistance Mechanisms
Share to Pharmacogenetics and Drug Metabolism

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32047295
DOI: 10.1038/s41416-019-0722-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progressionPMID 32047295Read ↗

UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.Semantic proximity Read ↗

UGT pharmacogenomicsSemantic proximity Read ↗

Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.Semantic proximity Read ↗

Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation.Semantic proximity Read ↗

Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.Semantic proximity Read ↗

Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.Semantic proximity Read ↗

Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.Semantic proximity Read ↗

Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.Semantic proximity Read ↗

UGT genomic diversity: beyond gene duplication.Semantic proximity Read ↗

Pharmacogenomics of Human UDP-Glucuronosyltransferases and Irinotecan ToxicitySemantic proximity Read ↗

Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas?Semantic proximity Read ↗

The Functionality of UDP-Glucuronosyltransferase Genetic Variants and their Association with Drug Responses and Human DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.